Compare Harley-Davidson Inc (HOG) vs Novavax Inc (NVAX) Price & Performance

Harley-Davidson (HOG) trades at $26.95, up 0.04% on the day, with a bullish technical signal and mixed earnings history. The company reported Q2 2026 EPS of $0.75, beating expectations, but revenue has declined from $5.8B in 2022 to $4.5B in 2025. Valuation ratios appear attractive with a P/E of 14.86 and P/B of 0.9, while analyst consensus is a hold with a $28.50 price target. Recent news includes a data breach investigation and a new product collaboration.

The outlook for HOG is cautious due to declining revenue and profit margins, offset by reasonable valuations and positive technical momentum. Key risks include tariff exposure, competitive pressures, and ongoing data security issues. Upside potential exists if the 'Back to the Bricks' strategy reverses sales trends, but investors should weigh fundamental weaknesses against technical strength.

Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.

The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.